GlycoMimetics, Inc. To Present New Preclinical Data On Its E-Selectin-CXCR4 Dual Antagonist At AACR Annual Meeting 2016

GAITHERSBURG, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that pre-clinical research demonstrating the potential of its third drug candidate, GMI-1359, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans. An oral presentation and a poster will highlight data on GMI-1359, a potent dual antagonist of both E-selectin and CXCR4, demonstrating anti-tumor activity in preclinical models of pancreatic cancer and acute myeloid leukemia (AML), respectively.

Back to news